Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 335.18M | 319.83M | 278.19M | 298.71M | 332.81M |
Gross Profit | 324.02M | 308.32M | 268.41M | 287.08M | 323.16M |
EBITDA | 264.16M | 259.94M | 151.99M | 212.99M | 303.95M |
Net Income | 137.99M | 135.65M | 23.06M | 62.19M | 135.37M |
Balance Sheet | |||||
Total Assets | 2.61B | 2.49B | 2.51B | 2.84B | 3.12B |
Cash, Cash Equivalents and Short-Term Investments | 24.29M | 22.35M | 19.29M | 37.41M | 43.34M |
Total Debt | 1.15B | 1.14B | 1.15B | 1.25B | 1.51B |
Total Liabilities | 1.23B | 1.21B | 1.22B | 1.32B | 1.60B |
Stockholders Equity | 1.37B | 1.25B | 1.27B | 1.51B | 1.51B |
Cash Flow | |||||
Free Cash Flow | 203.70M | 180.71M | 180.71M | 210.79M | 218.29M |
Operating Cash Flow | 207.77M | 184.45M | 185.34M | 210.86M | 232.15M |
Investing Cash Flow | -192.31M | -11.63M | 197.94M | 185.28M | -89.71M |
Financing Cash Flow | -13.57M | -169.72M | -401.25M | -402.99M | -111.76M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $5.99B | 34.06 | 7.02% | 4.00% | 43.27% | 80.97% | |
77 Outperform | $4.34B | 30.84 | 5.15% | 6.59% | 7.81% | 179.16% | |
75 Outperform | $3.27B | 22.20 | 10.56% | 5.15% | 7.44% | 4.23% | |
73 Outperform | $1.63B | 18.27 | 9.39% | 6.43% | 4.46% | 2.24% | |
68 Neutral | $6.03B | ― | -1.93% | 2.70% | 11.30% | ― | |
66 Neutral | £953.51M | 13.94 | 2.04% | 193.27% | 11.04% | 38.13% | |
48 Neutral | $2.60B | ― | -28.86% | 7.51% | 19.56% | -12.73% |
On June 2, 2025, National Health Investors, Inc. issued an investor presentation updating its investment pipeline to approximately $331.4 million, with $126.7 million in signed letters of intent, including a $71 million investment in senior housing operating partnerships. This update reflects NHI’s strategic focus on expanding its investment portfolio, potentially impacting its market positioning and offering insights into future growth opportunities for stakeholders.
The most recent analyst rating on (NHI) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on National Health Investors stock, see the NHI Stock Forecast page.
On May 21, 2025, National Health Investors, Inc. held its 2025 Annual Meeting of Stockholders, where 80.26% of the company’s common stock was represented. During the meeting, four directors were elected, an amendment to declassify the board was approved, executive compensation was affirmed, and BDO USA, P.C. was ratified as the independent auditor for 2025.
The most recent analyst rating on (NHI) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on National Health Investors stock, see the NHI Stock Forecast page.
On May 5, 2025, National Health Investors, Inc. released an investor update presentation available on their website. The update provides insights into the company’s financial strategies and operational plans, highlighting potential risks and uncertainties that could impact future performance, such as tenant financial health, regulatory changes, and economic conditions.
National Health Investors has released its Supplemental Information for the quarter ended March 31, 2025. This release provides stakeholders with updated financial data and insights into the company’s performance, which may influence their understanding of the company’s current market position and future prospects.